Expertise in
4
conditions

Dr. Carlos A. Fierro

General Practice
226 N 7th St, 
Kansas City, KS 
Expertise in
4
conditions
226 N 7th St, 
Kansas City, KS 

Overview

Carlos Fierro is a primary care provider, practicing in General Practice in Kansas City, Kansas.

Dr. Fierro is highly rated in 4 conditions, according to our data. His clinical expertise encompasses Carbuncle, Anthrax Infection, Cytomegalovirus Infection, and Togaviridae Disease.

He is actively involved in clinical research, co-authoring 17 peer reviewed articles and participating in 18 clinical trials.

Specialties

General Practice

Licenses

General Practice in KS

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

226 N 7th St, Kansas City, KS 66101

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

18 Clinical Trials

A Phase 3, Randomized, Double-blind, Parallel-group Trial to Evaluate the Lot Consistency, Immunogenicity, and Safety of AV7909 for Postexposure Prophylaxis of Anthrax in Healthy Adults
A Phase 3, Randomized, Double-blind, Parallel-group Trial to Evaluate the Lot Consistency, Immunogenicity, and Safety of AV7909 for Postexposure Prophylaxis of Anthrax in Healthy Adults
Enrollment Status: Completed
Publish Date: May 06, 2026
Intervention Type: Biological
Study Phase: Phase 3
A Phase 1/2, First-Time-in Human (FTiH), Randomized, Observer-blind, Placebo-controlled, Dose Escalation Study to Assess Safety, Reactogenicity and Immunogenicity of a Candidate Cytomegalovirus (CMV) Vaccine Comprising Recombinant Protein and Adjuvant When Administered Intramuscularly in Healthy Adults
A Phase 1/2, First-Time-in Human (FTiH), Randomized, Observer-blind, Placebo-controlled, Dose Escalation Study to Assess Safety, Reactogenicity and Immunogenicity of a Candidate Cytomegalovirus (CMV) Vaccine Comprising Recombinant Protein and Adjuvant When Administered Intramuscularly in Healthy Adults
Enrollment Status: Completed
Publish Date: March 02, 2026
Intervention Type: Biological, Combination product
Study Phase: Phase 1/Phase 2
A Phase 3 Safety, Immunogenicity, and Lot-Consistency Trial of the VLP-Based Chikungunya Vaccine PXVX0317 in Healthy Adults and Adolescents
A Phase 3 Safety, Immunogenicity, and Lot-Consistency Trial of the VLP-Based Chikungunya Vaccine PXVX0317 in Healthy Adults and Adolescents
Enrollment Status: Completed
Publish Date: August 30, 2024
Intervention Type: Biological
Study Phase: Phase 3
A Phase II Study of a Primary Dose of Investigational RSV Maternal Vaccine, Given Alone or With Boostrix, With a 2nd Dose Investigational RSV Maternal Vaccine
A Phase II Study of a Primary Dose of Investigational RSV Maternal Vaccine, Given Alone or With Boostrix, With a 2nd Dose Investigational RSV Maternal Vaccine
Enrollment Status: Completed
Publish Date: August 21, 2024
Intervention Type: Biological, Drug
Study Drugs: RSVPreF3, Boostrix-ex-US, Boostrix-US
Study Phase: Phase 2
A Phase 1/2, Randomized, Observer-Blind, Dose-Finding, Controlled, Parallel-Group, Two-Stage Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Adults Aged 18 to 64 Years
A Phase 1/2, Randomized, Observer-Blind, Dose-Finding, Controlled, Parallel-Group, Two-Stage Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Adults Aged 18 to 64 Years
Enrollment Status: Completed
Publish Date: April 18, 2024
Intervention Type: Biological
Study Phase: Phase 1/Phase 2
Safety and Immunogenicity of GSK's Rabies G SAM (CNE) Vaccine [GSK3903133A] in Healthy Adults.
Safety and Immunogenicity of GSK's Rabies G SAM (CNE) Vaccine [GSK3903133A] in Healthy Adults.
Enrollment Status: Completed
Publish Date: March 01, 2024
Intervention Type: Biological, Drug
Study Drugs: Rabies Glycoprotein G Vaccine, RabAvert Rabies Vaccine
Study Phase: Phase 1
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1™ Adjuvant in Adult Participants ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years)
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1™ Adjuvant in Adult Participants ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years)
Enrollment Status: Completed
Publish Date: December 21, 2023
Intervention Type: Biological, Other
Study Drug: SARS-CoV-2 rS/Matrix-M1 Adjuvant
Study Phase: Phase 3
A Phase 2 Open-Label Study to Assess the Safety and Immunogenicity of PXVX0317 (Chikungunya Virus Virus-Like Particle Vaccine [CHIKV VLP], Aluminum Hydroxide Adjuvanted)
A Phase 2 Open-Label Study to Assess the Safety and Immunogenicity of PXVX0317 (Chikungunya Virus Virus-Like Particle Vaccine [CHIKV VLP], Aluminum Hydroxide Adjuvanted)
Enrollment Status: Completed
Publish Date: July 03, 2023
Intervention Type: Biological
Study Phase: Phase 2
A Phase 4 Study to Assess the Safety and Immunogenicity of VAXCHORA (Cholera Vaccine, Live, Oral) in Children 2 to <18 Years of Age
A Phase 4 Study to Assess the Safety and Immunogenicity of VAXCHORA (Cholera Vaccine, Live, Oral) in Children 2 to <18 Years of Age
Enrollment Status: Completed
Publish Date: June 28, 2023
Intervention Type: Biological, Other
Study Phase: Phase 4
Phase I/II, Observer-blind, Safety, Reactogenicity and Immunogenicity Study of GSK Biologicals' Respiratory Syncytial Virus (RSV) Vaccine GSK3844766A in Subjects Aged 18-40 or 60-80 Years
Phase I/II, Observer-blind, Safety, Reactogenicity and Immunogenicity Study of GSK Biologicals' Respiratory Syncytial Virus (RSV) Vaccine GSK3844766A in Subjects Aged 18-40 or 60-80 Years
Enrollment Status: Completed
Publish Date: August 05, 2022
Intervention Type: Biological, Drug
Study Phase: Phase 1/Phase 2
View 9 Less Clinical Trials

17 Total Publications

Safety and Immunogenicity of the Cytomegalovirus Vaccine mRNA-1647 in Healthy Adults: Results from a Phase 2, Randomized, Controlled, Dose-Finding Trial with Long-Term Extension Follow-Up Through Month 48.
Safety and Immunogenicity of the Cytomegalovirus Vaccine mRNA-1647 in Healthy Adults: Results from a Phase 2, Randomized, Controlled, Dose-Finding Trial with Long-Term Extension Follow-Up Through Month 48.
Journal: Vaccines
Published: April 02, 2026
Similar Doctors
Expertise in
2
conditions
Della Taylor, NP
General Practice
Expertise in
2
conditions
Della Taylor, NP
General Practice

Mosaic Life Care At St. Joseph-Women's Health And Menopause Plaza 2

901 Heartland Rd Ste 4890, 
Saint Joseph, MO 
 (48.1 miles away)
816-271-1000
Languages Spoken:
English
See accepted insurances

Della Taylor is a General Practice provider practicing medicine in Saint Joseph, Missouri. Dr. Taylor is highly rated in 2 conditions, according to our data. Her clinical expertise encompasses Lichen Sclerosus, Vulvodynia, Vitiligo, and Hydrocele.

Expertise in
1
conditions
Melissa Farris, NP
General Practice
Expertise in
1
conditions
Melissa Farris, NP
General Practice

Mosaic Life Care At St. Joseph-Family Care North Pointe B And C

5210 N Belt Hwy # B, 
Saint Joseph, MO 
 (48.1 miles away)
816-271-1330
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Melissa Farris is a General Practice provider practicing medicine in Saint Joseph, Missouri. Dr. Farris is highly rated in 1 condition, according to our data. Her clinical expertise encompasses Chronic Rhinosinusitis with Nasal Polyps (CRSwNP).

Expertise in
1
conditions
Dr. Michael Francis
General Practice | Internal Medicine
Expertise in
1
conditions
Dr. Michael Francis
General Practice | Internal Medicine

Family Medical Clinic LLC

1700 NW Mock Ave, 
Blue Springs, MO 
 (19.2 miles away)
816-228-1500
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Michael Francis is a primary care provider, practicing in General Practice and Internal Medicine in Blue Springs, Missouri. Dr. Francis is highly rated in 1 condition, according to our data. His clinical expertise encompasses Cerebral Hypoxia, Shingles, Vasoconstriction, and Gerstmann Syndrome.

Frequently Asked Questions about Dr. Carlos A. Fierro

How do I make an appointment with Dr. Carlos A. Fierro?

You can book an appointment with Dr. Carlos A. Fierro by calling their office at 913-342-2277. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Carlos A. Fierro a top-rated expert for Carbuncle?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Carlos A. Fierro is classified as an Distinguished expert for Carbuncle, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Carlos A. Fierro specialize in?

While Dr. Carlos A. Fierro is a General Practice, they have specific expertise in Carbuncle, Anthrax Infection, and Cytomegalovirus Infection. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within General Practice.

Does Dr. Carlos A. Fierro participate in research or clinical trials?

Yes. Dr. Carlos A. Fierro has published 17 articles and abstracts on conditions like Carbuncle. You can view a list of Dr. Carlos A. Fierro's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Carlos A. Fierro accept my insurance?

Dr. Carlos A. Fierro accepts most major insurance plans, including Aetna and Blue Cross Blue Shield. We recommend calling the office directly at 913-342-2277 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Fierro's expertise for a condition
ConditionClose
    View All 9 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile